34. A nurse is educating a client with newly diagnosed autos…
34. A nurse is educating a client with newly diagnosed autosomal dominant polycystic kidney disease (ADPKD) who is starting tolvaptan (Jynarque). The nurse explains that tolvaptan inhibits vasopressin and helps to slow the progression of kidney cyst growth. Which of the following factors should be reported to the healthcare provider before initiation of the medication?